51 results about "Brain-derived neurotrophic factor" patented technology

The invention belongs to the technical field of protein, and relates to a peptide for promoting synthesis of a brain-derived neurotrophic factor (BDNF) as well as a preparation method and application of the peptide. The amino acid sequence of the peptide for promoting synthesis of the brain-derived neurotrophic factor BDNF is SGFSKHF, and the peptide has the main effects that damage of CORT (corticosterone) to PC12 cells can be protected, the peptide can be spontaneously combined with a TrkB receptor, the structure of a compound formed after combination is more stable, BDNF-TrkB-CREB pathway signal transduction can be activated, generation of the BDNF is promoted, and the effect of promoting synthesis of the brain-derived neurotrophic factor BDNF is achieved. Therefore, the occurrence and development of neurodegenerative diseases can be delayed.

The invention belongs to the technical field of immunodetection, and discloses a kit for detecting the ratio of proBDNF to maure BDNF based on structural dynamics guidance and a preparation method of the kit, the kit comprises a solid phase carrier and a detection reagent, the three antibodies are determined on the basis of full-length conformational kinetics analysis of brain-derived neurotrophic factors; the first capture antibody targets an innate disorder region (SEQ ID NO: 1) of a proBDNF propeptide region; the second capture antibody targets an innate disorder region (SEQ ID NO: 2) of a proBDNF propeptide region; the second capture antibody is a neo-epitope specific antibody, is specifically combined with an N terminal (SEQ ID NO: 2) exposed by maure BDNF enzyme digestion, and is combined with a free alpha-amino group strictly dependent on the first histidine; and the universal detection antibody is combined to a Loop 4 region (SEQ ID NO: 3) of the Mature structural domain. The problems of steric hindrance and cross reaction in traditional immunodetection are solved through a structural biology strategy, and accurate distinguishing and ratio quantification of proBDNF and maure BDNF are achieved.

The invention relates to application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for relieving depression or anxiety. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The invention develops a brand new application of the bifidobacterium animalis subsp. Lactis BLa80 strain, namely, the bifidobacterium animalis subsp. Lactis BLa80 strain is used for relieving depression or anxiety symptoms, specifically, the bifidobacterium animalis subsp. Lactis BLa80 strain can stimulate RIN14B cells to secrete 5-HT, can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety, can relieve hyperfunction of hypothalamic-pituitary-adrenal axis (HPA axis), and can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety. The inflammatory response of mice with depression and anxiety is relieved, the expression level of brain-derived neurotrophic factors in hippocampus of the mice with depression and anxiety is improved, the abundance of intestinal beneficial flora of the mice with depression and anxiety is improved, and the diversity of intestinal flora is increased.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus helveticus YM1922 for promoting brain development, improving concentration and nourishing nerves as well as a metabolite, a complex flora, a metabolite and application. The lactobacillus helveticus YM1922 is preserved in the China General Microbiological Culture Collection Center on September 10, 2024, and the preservation number of the lactobacillus helveticus YM1922 is CGMCC No. 31928. Fermentation metabolites of the strain can promote secretion of brain-derived neurotrophic factors, and thalli can inhibit production of intestinal tract D-gluconic acid in intestinal tracts. Therefore, the strain and the metabolite thereof have application potentials of promoting brain development, improving cognitive level, improving concentration and nourishing nerves, and can be prepared into products for playing corresponding roles.

The present invention relates to an exosome composition for improving sleep quality, comprising lavender exosomes, chamomile exosomes, and saffron exosomes. The exosome composition can increase the expression of GABA-related proteins in neurons, promote brain-derived neurotrophic factor (BDNF) expression in neurons, promote synaptic growth in neurons, increase CL levels in neurons, and inhibit the levels of inflammatory factors in microglia. The exosome composition can improve sleep quality caused by various physical discomforts, achieving a more pronounced effect than extracts of the same herbal remedies.

The present application belongs to the field of functional substance research, and particularly relates to a nutritional composition for promoting brain development and use thereof. The nutritional composition provided by the present application comprises essential active ingredients shown in (i) and (ii) as follows: (i) lysophosphatidylethanolamine; (ii) 3'-SL; wherein the essential active ingredient shown in (i) at least comprises lysophosphatidylethanolamine with a fatty acid chain with a length of 14-22 carbon atoms connected at the sn-1 position, and in the nutritional composition, the mass ratio of the essential active ingredient shown in (i) to the essential active ingredient shown in (ii) is 1:(1-450). The combination of lysophosphatidylethanolamine and breast milk oligosaccharide 3'-SL can effectively promote the overall development of the body, especially the brain development, and improve the relative gene expression amount of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, thereby effectively assisting the improvement of cognitive ability.

The present application relates to a nutritional composition, a product comprising the same and use thereof in the preparation of a product for alleviating synaptic plasticity impairment of a body. The nutritional composition comprises: docosahexaenoic acid (DHA) and / or a metabolic precursor thereof, sodium hyaluronate (SH), and lactoferrin (LF). When docosahexaenoic acid (DHA), sodium hyaluronate (SH) and lactoferrin (LF) are used in combination, they can synergistically alleviate synaptic plasticity impairment of a body, in particular, increase nerve growth factor (NGF) content and / or brain-derived neurotrophic factor (BDNF) content in PC12 cells of the body, and / or increase expression of synaptic-related proteins in PC12 cells of the body.

The application provides application of an acetyl dopamine compound in preparation of a medicine for improving insomnia, and belongs to the technical field of traditional Chinese medicine medicines, and the acetyl dopamine compound is acetyl dopamine dimer A extracted from cicada slough. Experiments prove that the acetyl dopamine dimer A can increase the content of brain-derived neurotrophic factor (BDNF) which plays an important role in the occurrence process of insomnia, reduce dopamine (DA) level, and has obvious effects on DA metabolites homovanillic acid (HVA) and dihydroxyphenyl acetic acid (DOPAC), thereby effectively improving insomnia. Through research on the effect of the acetyl dopamine dimer A on improving insomnia, the application obtains the basis of using the acetyl dopamine dimer A for improving insomnia, provides data support for research and development of the cicada slough as a medicine, and also provides a new medicinal source for improving insomnia.

The invention provides an ELISA reagent composition and kit for detecting brain-derived neurotrophic factors, and relates to the technical field of biological detection. The invention provides an ELISA (Enzyme-Linked Immunosorbent Assay) reagent composition for detecting brain-derived neurotrophic factors, the ELISA reagent composition is a sample diluent, and the sample diluent is composed of a buffer solution, bovine serum albumin, trehalose, polyethylene glycol 6000, propamidine dihydrochloride, glutathione and AEBSF. The ELISA reagent composition and the kit containing the ELISA reagent composition have good specificity and accuracy, and the coefficient of variation of a repetitive experiment is smaller than 10%, so that the kit has good repeatability and can be applied to detection of the content of BDNF in human serum.

The present invention provides adeno-associated virus (rAAV) vectors, in particular rAAV vectors comprising gene constructs carrying genes encoding tyrosine receptor kinase B (TrkB) and brain derived neurotrophic factor (BDNF). The invention also extends to pharmaceutical compositions comprising said rAAV vectors, and the use of these vectors and compositions in gene therapy for the prevention or treatment of a range of optic nerve and cochlear disorders or for promoting nerve regeneration and / or survival. The invention also provides a method of producing the rAAV vector.

To provide nucleic acids (including AAV expression cassettes), AAV vectors, and compositions for use in methods of treating and / or delaying the onset of diseases associated with mutations in mecp2 genes, such as Rett Syndrome.SOLUTION: Also provided herein are methods for treating a brain-derived neurotrophic factor (BDNF) - associated disease and / or delaying the onset of a brain-derived neurotrophic factor (BDNF) - associated disease. The present disclosure provides a nucleic acid comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, in a 5' to 3' direction, a 5' inverted terminal repeat (ITR), a synthetic activity-dependent promoter, a Rett syndrome-associated gene, and a 3' ITR.SELECTED DRAWING: None

The present invention belongs to the technical field of biomedicine, and specifically relates to a nociceptor skin organoid chip and its culture medium, construction method and application. A culture medium for a nociceptor skin organoid chip, the culture medium is composed of fetal bovine serum and the following components added to the fetal bovine serum: epidermal growth factor, bovine pituitary extract, Normocin, B27, nerve growth factor, insulin, hydrocortisone, human brain-derived neurotrophic factor and capsaicin. Using this culture medium to co-culture a skin chip with nociceptors to obtain a nociceptor skin organoid chip, which can be used for the verification of pain perception effects.

The invention discloses a lactobacillus reuteri source extracellular vesicle for preventing and relieving senescence syndrome by relieving immune cell senescence, and belongs to the technical field of microorganisms and the technical field of medicines. The extracellular vesicle provided by the invention can improve learning, memory and cognitive abilities; the muscle strength capability is enhanced; the exercise coordination ability is improved; the motion balance capability is enhanced; the blood inflammatory factor level is obviously reduced, and the anti-inflammatory factor level is improved; the enzyme activity of the senescence-related enzyme SA-beta-Gal in the brain tissue is obviously reduced; the expression levels of brain-derived neurotrophic factors and neurotransmitters are obviously up-regulated; the collagen content and the collagen synthesis capability in skin tissues are obviously improved. The lactobacillus reuteri CCFM1471 source extracellular vesicles do not generate toxic and side effects in a host body, can be used for preparing functional foods and / or dietary supplements and related beauty products with the effects of preventing and relieving senescence syndromes, and have huge application prospects.

The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and / or preventing or ameliorating at least one motor deficit in a subject in need thereof, such as in a subject with α-synucleinopathy, using the novel irisin peptides to modulate irisin-induced integrin signaling. The novel irisin peptides can also be used in methods for increasing expression of brain-derived neurotrophic factor (BDNF), and / or treating or preventing neurological diseases or disorders that would benefit from decreased neuronal cell death and / or increased neuronal survival in a subject. In addition, the novel irisin peptides may be used in methods for preventing or treating muscular atrophy or muscular dystrophy.

The invention relates to a human proBDNF mutant protein and a method for recombinantly producing a human brain-derived neurotrophic factor (BDNF) with biological activity.

The present application belongs to the technical field of nutrient research, and particularly relates to a nutrient composition for promoting brain development and use thereof. The nutrient composition provided by the present application comprises two necessary components: i) lysophosphatidyl ethanolamine; and ii) docosahexaenoic acid; and the mass ratio of the lysophosphatidyl ethanolamine to the docosahexaenoic acid in the nutrient composition is 1:(10-2100). The combination of lysophosphatidyl ethanolamine and docosahexaenoic acid can effectively promote the overall growth and development of the body, especially the brain development, increase the expression levels of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, and effectively assist the improvement of cognitive ability.

The invention discloses a central obesity early warning method and system based on BDNF dynamic monitoring, and relates to the field of dynamic monitoring of brain-derived neurotrophic factors.The method comprises the steps that the weight, the body length, the body temperature and the food intake of an experimental subject are obtained, fasting blood glucose and blood fat are detected through caudal vein blood sampling, a standardized physiological index data set is formed, and the standard physiological index data set is stored in a database; the method comprises the following steps: carrying out anatomical sampling on hypothalamus tissues, scapular brown adipose and perirenal adipose, and carrying out Western Blot detection to obtain the BDNF expression quantity of the hypothalamus tissues, the BDNF expression quantity of the scapular brown adipose tissues and the BDNF expression quantity of the perirenal adipose tissues; and acquiring the BDNF concentration time sequence data of the hypothalamus extracellular fluid through the implanted microdialysis module. According to the method, dynamic continuous monitoring of hypothalamic BDNF secretion is achieved through the implanted microdialysis technology, the rhythm disorder degree is quantified by calculating the sample entropy value, the limitation of a traditional static detection method is broken through, and early metabolic regulation abnormity can be captured more sensitively.

The present invention relates to a biomarker for distinguishing mood disorder-type psychiatric diseases and schizophrenia, and uses thereof. Based on a biomarker composition for mood disorder-type psychiatric diseases and schizophrenia comprising the serum proteins including leptin, tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), and brain-derived neurotrophic factor (BDNF), the present invention describes a composition for distinguishing mood disorder-type psychiatric diseases and schizophrenia, comprising reagents for measuring the expression levels of the five biomarker proteins, and a method for providing information for distinguishing between mood disorder-type psychiatric diseases and schizophrenia, using same.

This invention provides methods of detecting biomarkers in the biofluid of sepsis-associated encephalopathy (SAE) patients, including but not limited to glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase LI, Tan protein, Neurofilament light chain (NF-L), myelin basic protein (MBP), secretogranin, Copeptin, total all-spectrin, all-spectrin breakdown products (SBDP, including SBDP145, SBDP150, SBDP120 all-spectrin N-terminal fragment or SBDP150N), neuron specific enolase (NSE), mature brain derived neurotrophic factor (BDNF), and full-length Pro-BDNF. These biomarker peptides are markers of axonal and blood brain barrier integrity which can be used to diagnose SAE and to assess and predict cognitive performance and outcomes in acute presentations of sepsis.

The present application provides a kind of nutritional composition in the application of the product for improving learning, memory and cognitive ability.The nutritional composition includes animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose.Animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose can synergistically enhance the memory retention ability of the body, reduce the degree of learning and memory errors, and up-regulate the expression of oligodendrocyte transcription factor 2 coding gene, myelin basic protein coding gene and brain-derived neurotrophic factor coding gene, realize the double regulation of myelin formation and neurotrophic in hippocampus region of brain, synergistically improve the neural plasticity of central nervous system through gut-brain axis pathway, and then double improve the learning, memory and cognitive function of the body from the behavior and molecular level.

The application belongs to the technical field of biological drugs, and particularly relates to a preparation method of genetically modified human bone marrow mesenchymal stem cells and application thereof in treating nervous system diseases, in particular, multiple sclerosis. The human bone marrow mesenchymal stem cells are double-modified by brain-derived neurotrophic factor (BDNF) and anti-S1PR5 nanobody, so that the activity of the human bone marrow mesenchymal stem cells is improved, the survival of neurons or oligodendrocytes is promoted, cell apoptosis is inhibited, and myelin regeneration is promoted, and the human bone marrow mesenchymal stem cells can be applied to nervous system diseases, in particular, multiple sclerosis.

The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and / or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w / w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w / w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w / w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w / w of the composition. Such compositions are useful for improving memory and / or focus.

The invention discloses a genetically engineered membrane-anchored neurotrophic factor, an exosome and a preparation method thereof, and relates to the technical field of biology. The invention provides a recombinant brain-derived neurotrophic factor protein. The amino acid sequence of the recombinant brain-derived neurotrophic factor protein is shown as SEQ ID NO: 1. The genetically engineered membrane anchored neurotrophic factor exosome provided by the invention comprises a recombinant BDNF, and the recombinant BDNF has a transmembrane structural domain, an extracellular structural domain and an exosome sorting domain, can be highly enriched on an exosome membrane, retains the physiological activity of the BDNF, and promotes nerve cell survival and synaptic formation.

To provide a food and drink composition which has an excellent effect of promoting secretion of brain-derived neurotrophic factor (BDNF) from small intestinal endocrine cells from safe food materials.SOLUTION: There is provided a food and drink composition for promoting BDNF secretion from small intestinal endocrine cells containing 4'-demethylnobiletin as an active ingredient. The food and drink composition of the present disclosure may have an effect of reducing stress or depression in daily life, and alleviating anxiety, an effect of increasing vitality, energy or motivation, and / or an effect of reducing stomach discomfort or constipation in daily life. Since 4'-demethylnobiletin can be obtained by conversion from nobiletin of a citrus peel component by a koji mold fermentation method, the food and drink composition of the present disclosure is highly safe and has no concerns about side effects.SELECTED DRAWING: Figure 2

The present invention relates to human proBDNF muteins and methods for recombinantly producing biologically active human brain-derived neurotrophic factor (BDNF).

The invention discloses an injectable intelligent interface hydrogel microsphere with sequential controlled release as well as a preparation method and application of the injectable intelligent interface hydrogel microsphere. The microspheres are prepared from methacrylated gelatin, carboxymethyl cellulose nanocellulose and brain-derived neurotrophic factors, and the microspheres are treated by chitosan, so that the microspheres are shrunk and loaded with more brain-derived neurotrophic factors at the same time. On the basis, through polydopamine modification, the obtained microspheres have a sequential controlled release effect, and are beneficial to improving local inflammation after tissue defect and promoting regeneration and repair of defect tissues. In addition, the microspheres also have injectable characteristics, so that the microspheres can be conveniently applied to defect parts needing to be repaired. Acute-stage inflammatory response and subacute-stage and chronic-stage nerve fiber cell response can be regulated and controlled by utilizing the action of the sequential release biological factors of the microspheres and the multi-layer space structure, and spinal cord regeneration is promoted.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

The present invention relates to an extracellular vesicle loaded with a neuropeptide and, more specifically, to the use of an extracellular vesicle loaded with a neuropeptide for preventing, alleviating, or treating nervous system damage or nervous system diseases. The extracellular vesicle loaded with a neuropeptide according to the present invention was experimentally verified to have excellent effects in increasing brain-derived neurotrophic factor (BDNF) expression, promoting neuronal cell proliferation, and promoting neuronal cell differentiation. This means that the extracellular vesicle loaded with a neuropeptide of the present invention exhibits excellent neuroprotective and neuroregenerative effects and can thus be variously used in the field of treating nervous system damage or nervous system diseases.

To provide a composition capable of reducing a feeling of eye fatigue or unpleasantness and capable of treating or preventing dry eye.SOLUTION: The present invention provides a tear fluid secretion promoter that comprises fructophilic lactic acid bacteria, or a composition containing the same. It is preferable that the composition is ingested or administered orally in the form of food or the like, thereby reducing a feeling of eye fatigue or unpleasantness resulting from decreased eye moisture and enabling treatment or prevention of dry eye. It is preferable that the tear fluid secretion promoter is capable of raising a concentration of interleukin-10 (IL-10) in plasma or enhancing an expression level of brain-derived neurotrophic factor (BDNF).SELECTED DRAWING: Figure 1

The application discloses a probiotic with the function of improving depression and a microecological preparation and application thereof, and has the characteristics that the probiotic comprises fermented Lactobacillus muci-deprounc PC17 with the preservation number of CGMCC No.33866; the active ingredient of the lactic acid bacteria microecological preparation comprises the bacterial body of the fermented Lactobacillus muci-deprounc PC17; the microecological preparation is prepared by inoculating the fermented Lactobacillus muci-deprounc PC17 into a fermentation culture medium at a proportion of 1-5% in volume ratio to prepare the lactic acid bacteria microecological preparation; and the lactic acid bacteria microecological preparation can be used to prepare an antidepressant drug, has the advantages that the lactic acid bacteria microecological preparation can promote RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reduce the levels of interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and adrenocorticotropic hormone in serum, improve the levels of butyric acid and brain-derived neurotrophic factor in serum, and obviously improve the depression-like behavior of CUMS depression model mice.